Literature DB >> 19104491

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.

D Mattei, M Feola, F Orzan, N Mordini, D Rapezzi, A Gallamini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19104491     DOI： 10.1038/bmt.2008.415

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  28 in total

Review 1.  An update on cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman
Journal:  Trends Cardiovasc Med       Date:  2014-07-22       Impact factor: 6.677

Review 2.  Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Authors:  Rongras Damrongwatanasuk; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

Review 3.  Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Authors:  Fatima A Ballout; Ahmad S Manshad; Tochukwu M Okwuosa
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

Review 4.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 5.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors:  Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

Review 6.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

7.  Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.

Authors:  Dariusz Zakrzewski; Ilona Seferynska; Krzysztof Warzocha; Tomasz Hryniewiecki
Journal:  Int J Hematol       Date:  2012-05-26       Impact factor: 2.490

Review 8.  Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.

Authors:  Mary C Barber; Michael J Mauro; Javid Moslehi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 9.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Authors:  Javid J Moslehi; Michael Deininger
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

10.  Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Authors:  Koung Jin Suh; Ji Yun Lee; Dong-Yeop Shin; Youngil Koh; Soo-Mee Bang; Sung-Soo Yoon; Seonyang Park; Inho Kim; Jeong-Ok Lee
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.